Low Dose Research towards Multidisciplinary Integr.. (DOREMI)
Low Dose Research towards Multidisciplinary Integration
Start date: Jan 1, 2010,
End date: Dec 31, 2015
The aim of DoReMi is to promote the sustainable integration of low dose risk research in Europe in order to aid the effective resolution of the key policy questions identified by the High Level Expert Group (HLEG) on Low Dose Risk Research (www.hleg.de). DoReMi provides an operational tool for the development of the proposed MELODI platform (Multidisciplinary European Low Dose Risk Re-search Initiative) consisting of major national bodies and research programmes that have long term commitment in low dose risk research in Europe. A Letter of Intent between the core members of MELODI has been signed in April 2009. During the project, new members are expected to join the Initiative.The Joint Programme of Activities (JPA) of DoReMi includes: (i) a Joint Programme of Research (JPR) covering the issues outlined above and providing an overview of the needs for research infra-structures of pan-European interest and facilitating multilateral initiatives leading to better use and development of research infrastructures; (ii) a Joint Programme of Integration (JPI) to develop a coor-dinated European roadmap for the long term needs of the key players in Europe; and (iii) a Joint Pro-gramme for the Spreading of Excellence (JPSE), covering knowledge management, training and mo-bility and its implementation. The JPR focuses on the areas identified by the HLEG as the most prom-ising in terms of addressing/resolving the key policy questions, namely: the shape of dose response curve for cancer, individual susceptibilities and non-cancer effects. Radiation quality, tissue sensitivity and internal exposures will be addressed as cross cutting themes within the three main research areas. A substantial proportion of the JPA will be dedicated to the joint programme of research. The pro-gramme describes a multidisciplinary approach including interfaces with the broader biological toxico-logical and epidemiological communities. Strategic planning will be carried out in close collaboration with MELODI. The long term Strategic Research Agenda (SRA) will be developed by MELODI, whereas DoReMi research priorities are based on a shorter term Transitional Research Agenda (TRA), focusing on goals that are feasible to achieve within the 6 year project and areas where barriers need to be removed in order to proceed with the longer term strategic objectives.
Get Access to the 1st Network for European Cooperation